Regeneron Stock Valuation

REGN
 Stock
  

USD 643.29  6.95  1.09%   

What is the current enterprise value of Regeneron Pharmaceuticals? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Regeneron Pharmaceuticals, is its stock price multiplied by the total number of shares outstanding, calculating Regeneron Pharmaceuticals' enterprise value requires a different approach. It uses Regeneron Pharmaceuticals' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Free Cash Flow is expected to rise to about 933.6 M this year. Enterprise Value is expected to rise to about 37.1 B this year.
Regeneron Pharmaceuticals holds a recent Real Value of $668.41 per share. The prevailing price of the company is $643.29. At this time, the company appears to be undervalued. Our model determines the value of Regeneron Pharmaceuticals from analyzing the company fundamentals such as Operating Margin of 57.03 %, return on equity of 49.75 %, and Shares Outstanding of 105.72 M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support picking up undervalued entities and discarding overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
  
Regeneron Pharmaceuticals Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Regeneron Pharmaceuticals's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Regeneron Most Recent Valuation Data

Price Book
3.38
Enterprise Value
65.1 B
Enterprise Value Ebitda
9.72
Price Sales
4.95
Forward PE
15.53
Trailing PE
12.83
Undervalued
Today 643.29
Please note that Regeneron Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Regeneron Pharmaceuticals is based on 3 months time horizon. Increasing Regeneron Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Regeneron Pharmaceuticals is useful when determining the fair value of the Regeneron stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Regeneron Pharmaceuticals. Since Regeneron Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regeneron Stock. However, Regeneron Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
572.71
Downside
668.41
Real Value
670.47
Upside
Estimating the potential upside or downside of Regeneron Pharmaceuticals helps investors to forecast how Regeneron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regeneron Pharmaceuticals more accurately as focusing exclusively on Regeneron Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates (5)
LowProjected EPSHigh
66.3766.8767.87
Details
Hype
Prediction
LowEstimated ValueHigh
634.76636.82638.88
Details
Naive
Forecast
LowNext ValueHigh
685.31687.37689.43
Details
15 Analysts
Consensus
LowTarget PriceHigh
575.00706.85844.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Regeneron Pharmaceuticals' intrinsic value based on its ongoing forecasts of Regeneron Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Regeneron Pharmaceuticals' closest peers. When choosing an evaluation method for Regeneron Pharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Regeneron Pharmaceuticals Investments

1.33 Billion

Regeneron Valuation Drivers Correlation

Many accounts on the financial statements of Regeneron Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting Regeneron's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Regeneron
Click cells to compare fundamentals

Regeneron Valuation Trend

Knowing Regeneron Pharmaceuticals' actual value is paramount for traders to make sound investment determinations. Regeneron Pharmaceuticals' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Regeneron Pharmaceuticals' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Regeneron Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Regeneron Market Cap

Regeneron Pharmaceuticals is currently regarded as top stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is at this time estimated at about 2 Trillion. Regeneron Pharmaceuticals holds roughly 69.76 Billion in market capitalization claiming about 3% of stocks in Biotechnology industry.
Capitalization  Workforce  Valuation  Revenue  Total debt

Regeneron Pharmaceuticals Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Regeneron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Regeneron Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regeneron Pharmaceuticals competition to find correlations between indicators driving Regeneron Pharmaceuticals's intrinsic value. More Info.
Regeneron Pharmaceuticals is currently regarded as top stock in beta category among related companies. It is currently regarded as top stock in price to earning category among related companies reporting about  33.45  of Price to Earning per Beta. Price to Earnings Ratio is expected to rise to 41.69 this year. Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to rise to about 10.4 B this year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Regeneron Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regeneron Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regeneron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Regeneron Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Regeneron Pharmaceuticals and how it compares across the competition.

About Regeneron Pharmaceuticals Valuation

The stock valuation mechanism determines the current worth of Regeneron Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Regeneron Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Regeneron Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Regeneron Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Regeneron Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regeneron Pharmaceuticals. We calculate exposure to Regeneron Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Regeneron Pharmaceuticals's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Full Time Employees
10.7 K
Service Category
Biotechnology
Employer Id Number
13-3444607
Last ReportedProjected for 2022
Gross Profit4.1 B4.4 B
Profit Margin 50.25  54.21 
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.

Regeneron Pharmaceuticals Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Regeneron Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio3.95
Earnings Quarterly Growth-12.70%
Revenue Growth17.30%
Enterprise Value To Ebitda6.20
Earnings Growth-14.70%
Enterprise Value To Revenue3.53

Regeneron Pharmaceuticals Current Valuation Indicators

Valuation refers to the process of determining the present value of Regeneron Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Regeneron we look at many different elements of the entity such as Regeneron's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Regeneron Pharmaceuticals' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Regeneron Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Regeneron Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Regeneron Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Regeneron Pharmaceuticals' worth.
Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
70.5 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.